Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Indinavir sulfate
Indinavir · 6 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Indinavir sulfate | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
| Efavirenz | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Nelfinavir mesylate | DRUG | - |
| Ritonavir | DRUG | - |
Inclusion Criteria Patients must have: * HIV-1 seropositive status. * CD4 count greater than 100 cells/mm3. * Viral RNA above 10,000 copies/mL. * Consent from parent or guardian if less than 18 years of age. Exclusion Criteria Prior Medication: Excluded: * Prior therapy with protease inhibitor...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Indinavir is used to treat HIV Infections. It is an antiretroviral medicine studied in adults, adolescents, and children living with HIV, including patients who had failed prior protease inhibitor treatment. It has been evaluated both as part of combination regimens and at different dose levels alongside nucleoside analogue reverse transcriptase inhibitors.
Indinavir is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor responsible for the clinical development program of the drug in HIV Infections.
Indinavir has been studied in Phase 3 clinical development for HIV Infections. Its trial program also includes Phase 2 and Phase 1 studies. The Phase 3 study compared two dose levels of Indinavir combined with two nucleoside analogue reverse transcriptase inhibitors in HIV-infected patients.
Indinavir has been evaluated in six completed clinical trials, including NCT00002406, a Phase 3 comparison of two dose levels with two nucleoside analogue reverse transcriptase inhibitors, and NCT00002361, a Phase 2 study in patients who had failed prior protease inhibitor treatment. Other studies include NCT00002351 and NCT00002235.
Yes, Indinavir sulfate is another name for Indinavir. The two names refer to the same medicine, so searches for either term describe the same HIV treatment developed by Merck & Company, Inc.
Across six completed clinical trials, 918 patients have been enrolled in studies of Indinavir for HIV Infections. The largest of these, NCT00002406, enrolled 350 participants, while the smallest, NCT00002235, enrolled 6.